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(57) ABSTRACT 
Pharmaceutical compounds comprising bridged nicotine 
analogs of N-octylnicotinium iodide (NONI) having selec 
tive antagonist properties at (x3[32-containing nicotinic 
receptor subtypes, and compositions containing these com 
pounds. The compounds and compositions are used to treat 
central nervous system pathologies. 
36 Claims, No Drawings 
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BRIDGED NICOTINE COMPOUNDS FOR 
USE IN THE TREATMENT OF CNS 
PATHOLOGIES 
RELATED APPLICATION 
This application claims priority from US. Provisional 
Patent Application Serial No. 60/228,76, ?led Aug. 30, 
2000, incorporated herein by reference. 
FIELD OF THE INVENTION 
This invention relates to bridged nicotine analogs of 
N-octylnicotinium iodide (NONI) that have selective 
antagonist properties at (x3[32-containing nicotinic receptor 
subtypes and to a method of using such compounds to treat 
central nervous system pathologies. The present invention 
also relates to pharmaceutical compositions containing these 
compounds, as Well as various uses thereof. 
BACKGROUND OF THE INVENTION 
Formula (I) beloW shoWs the structure of S-(—)-nicotine 
(NIC), Which activates neuronal nicotinic receptors evoking 
release of dopamine (DA) from presynaptic terminals in the 
central nervous system (CNS). NIC is a legal substance of 
dependence that produces many of its effects on the CNS, 
some of Which may be considered to be bene?cial, e.g., 
mood elevation, arousal and learning and memory enhance 
ment. NIC produces its effect by binding to a family of 
ligand-gated ion channels, stimulation by acetylcholine 
(ACh) or NIC causes the ion channel to open, and cations to 
?ux With a resulting rapid (in msec) depolariZation of the 
target cell. 
Over the last 12 years, there has been a substantial 
increase in studies on brain nicotinic receptors. These nico 
tinic receptors are composed of four subunit domains: 2a, [3, 
y and 6 or e. Neuronal nicotinic receptors are composed of 
only tWo subunits, 0t and [3 and are believed to assemble With 
the general stoichiometry of 20. and 3[3. Eight subtypes of 
the ot subunit (a2 to Q9) and three subtypes of the [3 unit ([32 
to [34) are found in CNS. The most common nicotinic 
receptor species in the brain is composed of tWo (x4 and 
three [32 subunits, i.e., (x4[32. These subunits display 
different, but overlapping, patterns of expression in the 
brain. 
For the most part, the actual subunit compositions and 
stoichiometries of nicotinic receptors in the brain remain to 
be elucidated. Thus, neuronal nicotinic receptor subtype 
diversity originates from differences in the amino acid 
sequence at the subunit level and from the multiple combi 
nations of assemblies of subunits into functional receptor 
proteins afford Wide diversity of pharmacological speci?c 
ity. 
In spite of the extensive diversity in neuronal nicotinic 
receptor messenger RNA expression, only a limited number 
of tools are available to study the pharmacology of native 
receptors. Radioligands are used in many such studies. 
[3H]NIC appears to label the same sites in the brain as 
[3H]ACh. It has been estimated that over 90% of [3H]NIC 
binding in the brain is due to association With a receptor that 
is composed of (X4 and [32 subunits. Also, nicotinic receptor 
subtypes can be studied using an assay such as NIC-evoked 
[3H]DA release from rat straital slices. Nicotinic receptors 
are located in the cell body and terminal areas of the 
nigrostriatal system. NIC facilitates DA release from striatal 
nerve terminals. Studies strongly suggest that the [3H]DA 
release assay is useful to probe the (x3[32-containing subtype 
of the nicotinic receptor. 
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The structural and functional diversity of CNS nicotinic 
receptors has stimulated a great deal of interest in develop 
ing novel, subtype-selective agonists. Some of these ago 
nists are currently being evaluated in clinical trials for 
cognitive enhancement and neuroprotective effects poten 
tially bene?cial for diseases such as AlZheimer’s and Par 
kinson’s Disease. Surprisingly, little attention a has been 
focused on developing subtype-selective antagonists for 
neuronal nicotinic receptors. 
A class pyridino N-substituted nicotine analogs having 
formula (II) beloW are knoWn antagonists that inhibit nico 
tine evoked [3H]DA release from dopaminergic nerve ter 
minals in the brain. The abbreviated nomenclature is given 
in parentheses. 
0"‘ 
l \ \\\ / CH3 
N 
S- (—)nicotine (NIC) 
l T 
@/ CH3 
9 N 
I l 
R 
a) R = - (CH2)7CH3 (NONI) 
b) R = - (CH2)8CH3 (NNNI) 
c) R = - (CH2)9CH3 (NDNI) 
d) R = - (CH2)10CH3 (NUNI) 
e) R = - (CH2)11CH3 (NDDNI) 
These compounds are useful in the treatment of nicotine 
abuse, smoking cessation therapy, as an antidote for nicotine 
intoxication, treatment of cognitive disorders such as AlZhe 
imer’s disease and for the treatment of Parkinson’s disease. 
The compounds and their method of use Were the subject of 
US. Pat. No. 5,691,365, issued Nov. 25, 1997. The content 
of this patent is incorporated herein by reference. 
The invention disclosed herein is directed to another neW 
class of efficacious and subtype-selective nicotinic antago 
nists at nicotinic receptors in the CNS. These compounds 
comprise bridged nicotine analogs of NONI. 
SUMMARY OF THE INVENTION 
The present invention provides; for bridged nicotine ana 
logs of N-octylnicotinium iodide (NONI) compounds hav 
ing potent and selective antagonistic activity at neuronal 
nicotinic receptor subtypes. The compounds competitively 
inhibit CNS acting nicotinic receptor agonists that are acting 
as putative 0L3[32 neuronal nicotinic receptor in the CNS. 
A preferred embodiment of the invention provides for a 
method of antagoniZing the nicotinic receptor comprising 
administering of a pharmaceutically effective amount of a 
compound of the invention. 
Still another embodiment the invention provides a method 
for the treatment of psychostimulant abuse (including nico 
tine abuse, amphetamine abuse, methamphetamine abuse, 
alcohol abuse and cocaine abuse), as smoking cessation 
therapy, as an antidote for nicotine intoxication comprising 
administering of a pharmaceutically effective amount of a 
compound according to the invention, as a therapeutic agent 
US 6,503,922 B2 
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for the treatment of pathologies of the GI tract, including 
irritable bowel syndrome, colitis and related disorders. 
This invention further provides a method of treatment of 
CNS disorders associated With the alteration of normal 
neurotransmitter release in the brain, including conditions 
such as AlZheimer’s disease as Well as other types of 
dementia, Parkinson’s disease, cognitive dysfunction 
(including disorders of attention, focus and concentration), 
attention de?cit syndrome, affective disorders, mood and 
emotional disorders such as depression, panic anXiety and 
psychosis, Tourette’s syndrome, schiZophrenia, eating dis 
orders and the control of pain comprising administering of 
a pharmaceutically effective amount of a compound accord 
ing to the invention. 
The above and other objects of the invention Will become 
readily apparent to those of skill in the relevant art from the 
folloWing detailed description and ?gures, Wherein only the 
preferred embodiments of the invention are shoWn and 
described, simply by Way of illustration of the best mode of 
carrying out the invention. As is readily recogniZed the 
invention is capable of modi?cations Within the skill of the 
relevant art Without departing from the spirit and scope of 
the invention. 
DETAILED DESCRIPTION OF THE 
INVENTION 
The present invention provides, novel bridged-ring com 
pounds corresponding to the schematic structure formulas 
III and IV beloW: 
III 
Wherein 
A is a 1, 2 or 3 atom bridging species selected from 
straight chain or branched chain alkylene moiety hav 
ing up to 3 atoms in the backbone thereof, or a 
substituted alkenylene moiety having up to 3 atoms in 
the backbone thereof, or a C(O), O, C(S), S, S(O) or 
S(O)2 containing alkylene moiety, provided hoWever, 
that any heteroatom contained in Ais separated from N 
by at least one carbon atom; 
B is a 1, 2 or 3 atom bridging species selected from 
straight chain or branched chain alkylene moiety hav 
ing up to 3 atoms in the backbone thereof, or a 
substituted alkenylene moiety having up to 3 atoms in 
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the backbone thereof, or a C(O), O, N(Y1), C(S), S, 
S(O) or S(O)2 containing alkene moiety, Wherein Y1 is 
hydrogen or loWer alkyl or aryl; 
R1 is selected from hydrogen, loWer alkyl (e.g., C1—C1O 
alkyl, preferably C1—C6 alkyl, and more preferably 
methyl, ethyl, isopropyl or isobutyl) or an aromatic 
group-containing species; 
R2 is selected from hydrogen or loWer alkyl; 
R3, R4 and R5 are each independently selected from 
hydrogen; alkyl; substituted alkyl; cycloalkyl; substi 
tuted cycloalkyl; alkenyl; substituted alkenyl; alkynyl; 
substituted alkynyl; aryl; substituted aryl; alkylaryl; 
substituted alkylaryl; arylalkyl; substituted arylalkyl; 
arylalkenyl; substituted arylalkenyl; arylalkynyl; sub 
stituted arylalkynyl; heterocyclic; substituted heterocy 
clic; tri?uoromethyl; halogen; cyano; nitro; S(O)Y2, 
S(O)2Y2, S(O)2OY2 or S(O)2NHY2, Wherein each Y2 
is independently hydrogen, loWer alkyl, alkenyl, alky 
nyl or aryl, provided, hoWever, that When R3, R4 or R5 
is S(O)Y2, Y2 is not hydrogen, and further provided 
that When Y2 is alkenyl or alkynyl, the site of unsat 
uration is not conjugated With a heteroatom; C(O)Y3, 
Wherein Y3 is selected from hydrogen, alkyl, substi 
tuted alkyl, alkoXy, alkylamino, alkenyl, substituted 
alkenyl, alkynyl, substituted alkynyl, aryl, substituted 
aryl, aryloXy, arylamino, alkylaryl, substituted 
alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, 
substituted arylalkenyl, arylalkynyl, substituted 
arylalkynyl, heterocyclic, substituted heterocyclic or 
tri?uoromethyl, provided, hoWever, that the carbonyl 
functionality is not conjugated With an alkenyl or 
alkynyl functionality; OY4 or N(Y“)2 Wherein each Y4 
is independently selected from hydrogen, alkyl, substi 
tuted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, 
substituted alkenyl, alkynyl, substituted alkynyl, aryl, 
substituted aryl, alkylaryl, substituted alkylaryl, 
arylalkyl, substituted arylalkyl, arylalkenyl, substituted 
arylalkenyl, arylalkynyl, substituted arylalkynyl, 
heterocyclic, substituted heterocyclic, acyl, 
tri?uoromethyl, alkylsulfonyl or arylsulfonyl, 
provided, hoWever, that the OY4 or N(Y“)2 function 
ality is not conjugated With an alkenyl or alkynyl 
functionality; SY5 Wherein Y5 is selected from 
hydrogen, alkyl, substituted alkyl, cycloalkyl, substi 
tuted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, 
substituted alkynyl, aryl, substituted aryl, alkylaryl, 
substituted alkylaryl, arylalkyl, substituted arylalkyl, 
arylalkenyl, substituted arylalkenyl, arylalkynyl, sub 
stituted arylalkynyl, heterocyclic, substituted heterocy 
clic or tri?uoromethyl, provided, hoWever, that the SY5 
functionality is not conjugated With an alkenyl or 
alkynyl functionality; 
R6 is selected from alkyl, substituted alkyl, cycloalkyl, 
substituted cycloalkyl, alkenyl, substituted alkenyl, 
alkynyl, substituted alkynyl, aryl, substituted aryl, 
arylalkyl, substituted arylalkyl, arylalkenyl, substituted 
arylalkenyl, arylalkynyl, substituted arylalkynyl, het 
erocyclic or substituted heterocyclic; and 
X is selected from chlorine, bromine, iodine, HSO4, 
1/2SO2, CH3SO3, p-TsO or CF3SO3. 
The junction betWeen rings a and b can be either cis or 
trans geometry. The present invention includes all possible 
diastereomers and all enantiomeric forms as Well as racemic 
mixtures. The compounds can be separated into substan 
tially optically pure compounds. The compounds of the 
invention are nicotinic receptor antagonists. They inhibit 
NIC-evoked [3H]-DA release and inhibit [3H]-NIC binding. 
US 6,503,922 B2 
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It is preferred that A is either CH2 or CHZCHZ; B is CH2, 
CHZCH2 or N(Y1) Where Y1 is either hydrogen or methyl; 
R1 is a C1—C1O alkyl or more preferably a C1—C6 alkyl or 
even more preferably a C —C4 alkyl such as a methyl, ethyl, 
isopropyl or isobutyl; R is hydrogen; R3, R4 and R5 are 
individually selected from the group consisting of hydrogen, 
halogen, alkyl and alkanoyl; R6 is a C4—C19 unbranched 
alkyl; and X is iodine. 
As employed herein, the meaning of the aforementioned 
terms are de?ned as folloWs: 
“loWer alkyl” refers to straight or branched chain alkyl 
radicals having in the range of 1 up to 4 carbon atoms; 
“alkyl” refers to straight or branched chain alkyl radicals 
having in the range of 1 up to 19 carbon atoms and 
“substituted alkyl” refers to alkyl radicals further bear 
ing one or more substituents such as hydroXy, alkoXy 
(of a loWer alkyl group), mercapto (of a loWer alkyl 
group), aryl, heterocyclic, halogen, tri?uoromethyl, 
cyano, nitro, amino, carboXyl, carbanate, sulfonyl, 
sulfonamide, and the like. 
“cycloalkyl” refers to cyclic ring-containing radicals con 
taining in the range of 3 up to 8 carbon atoms and 
“substituted cycloalkyl” refers to cycloalkyl radicals 
further bearing one or more substituent as set forth 
above; 
“alkenyl” refers to straight or branched chain hydrocarbyl 
radicals having at least one carbon-carbon double bond, 
and having in the range of 2 up to 19 carbon atoms and 
“substituted alkenyl” refers to alkenyl radicals further 
bearing one or more substituents as set forth above; 
“alkynyl” refers to straight or branched chain hydrocarbyl 
radicals having at least one carbon-carbon triple bond, 
and having in the range of 2 up to 19 carbon atoms and 
“substituted alkynyl” refers to alkynyl radicals further 
bearing one or more substituents as set forth above; 
“aryl” refers to aromatic radicals having in the range of 6 
up to 24 carbon atoms and “substituted aryl” refers to 
aryl radicals further bearing one or more substituents as 
set forth above; 
“alkylaryl” refers to alkyl-substituted aryl radicals and 
“substituted alkylaryl” refers to alkylaryl radicals fur 
ther bearing one or more substituents as set forth above; 
“arylalkyl” refers to aryl-substituted alkyl radicals and 
“substituted arylalkyl” refers to arylalkyl radicals fur 
ther bearing one or more substituents as set forth above; 
“arylalkenyl” refers to aryl-substituted alkenyl radicals 
and “substituted arylalkenyl” refers to arylalkenyl radi 
cals further bearing one or more substituents as set 
forth above; 
“arylalkynyl” refers to aryl-substituted alkynyl radicals 
and “substituted arylalkynyl” refers to arylalkynyl radi 
cals further bearing one or more substituents as set 
forth above; 
“aroyl” refers to aryl-substituted species such as benZoyl 
and “substituted aroyl” refers to aroyl radicals further 
bearing one or more substituents as set forth above; 
“heterocyclic” refers to cyclic radicals containing one 
or more heteroatoms as part of the ring structure, and 
having in the range of, 3 up to 24 carbon atoms and 
“substituted heterocyclic” refers to heterocyclic radi 
cals further bearing one or more substituents as set 
forth above; “acyl” refers to alkyl-carbonyl species; 
“halogen” refers to ?uoride, chloride, bromide or iodide 
radicals; and 
“an effective amount”, When used in reference to com 
pounds of the invention, refers to doses of compound 
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suf?cient to provide circulating concentrations high 
enough to impart a bene?cial effect on the recipient 
thereof. Such levels typically fall in the range of about 
0.001 up to about 100 mg/kg/day, With levels in the 
range of about 0.05 up to about 10 mg/kg/day being 
preferred. 
The novel compounds of this invention are substantially 
optically pure. 
The bridged nicotine analogs of NONI include com 
pounds having formulas V and VI. The abbreviated nomen 
clature is given in parentheses. 
V 
a) R = ' (CH2)7CH3 (AC0) 
b) R = - (CH2)8CH3 (ACN) 
c) R = - (CH2)9CH3 (ACD) 
d) R = ' (CH2)10CH3 (ACU) 
6) R = — (CH2)11CH3 (ACDD) 
VI 
a) R = - (CH2)7CH3 (BCO) 
b) R = - (CH2)8CH3 (BCN) 
c) R = - (CH2)9CH3 (BCD) 
d) R = ' (CH2)10CH3 (BCU) 
6) R = — (CH2)11CH3 (BCDD) 
These compounds potently, competitively and selectively 
inhibit dopamine release induced by nicotine in superfused 
rat striatal slice preparations, While exhibiting Weak insig 
ni?cant inhibition of [3H]-nicotine and [3H]-MLAbinding to 
rat striatal membranes. These compounds include, but are 
not limited to, the folloWing speci?c compounds: 
cis-1-methyl-8-octyl-2,3,3a,4,5,9b-heXahydro-1H-pyrrolo 
[3,2-h]isoquinolin-8-ium iodide (ACO), 
cis-1-methyl-8-nonyl-2,3,3a,4,5,9b-heXahydro-1H-pyrrolo 
[3,2-h]isoquinolin-8-ium iodide (ACN), 
cis-8-decyl-1-methyl-2,3,3a,4,5,9b-heXahydro-1H-pyrrolo 
[3,2-h]isoquinolin-8-ium iodide (ACD), 
cis-1-methyl-8-undecyl-2,3,3a,4,5,9b-heXahydro-1H 
pyrrolo[3,2-h]isoquinolin-8-ium iodide (ACU), 
cis-8-dodecyl-1-methyl-2,3,3a,4,5,9b-heXahydro-1H 
pyrrolo[3,2-h]isoquinolin-8-ium iodide (ACDD). 
cis-1-methyl-6-octyl-2,3,3a,4,5,9b-heXahydro-1H-pyrrolo 
[2,3-f]isoquinolin-6-ium iodide (BCO), 
cis-1-methyl-6-nonyl-2,3,3a,4,5,9b-heXahydro-1H-pyrrolo 
[2,3-f]isoquinolin-6-ium iodide (BCN), 
cis-6-decyl-1-methyl-2,3,3a,4,5,9b-heXahydro-1H-pyrrolo 
[2,3-f]isoquinolin-6-ium iodide (BCD), 
cis-1-methyl-6-undecyl-2,3,3a,4,5,9b-heXahydro-1H 
pyrrolo[2,3-f]isoquinolin-6-ium iodide (ECU), and 
cis-6-dodecyl-1-methyl-2,3,3a,4,5,9b-heXahydro-1H 
pyrrolo[2,3-f]isoquinolin-6-ium iodide (BCDD). 
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These compounds can be prepared from corresponding 
free bases by reaction With an appropriate alkyl iodide using 
techniques knoWn to those skilled in the art of organic 
synthesis. The requisite free bases can be synthesiZed using 
the techniques set forth by Chavdarian et al., J Org. Chem. 
48:492 (1983), Glassco et al.,J. Med. Chem. 36:3381 (1993) 
and Vernier et al., Bioorg. Med. Chem. Lett. 812173 (1998). 
The invention Will noW be described in greater detail by 
reference to the following non-limiting examples. 
EXAMPLE 1 
Preparation of cis-1-Methyl-8-octyl-2,3,3a,4,5,9b 
hexahydro-1H-pyrrolo[3,2-h]-isoquinolin-8-ium 
iodide (ACO) 
To a stirred solution of cis-1-methyl-2,3,3a,4,5,9b 
hexahydro-1H-pyrrolo[3,2-h]isoquinoline (100 mg, 0.53 
mmol) in AcOH (2 ml) Was added 1-iodooctane (383 mg, 
1.59 mmol). The mixture Was heated at re?ux under nitrogen 
for 3 days. AcOH Was evaporated and the residue Was 
dissolved in CHCl3. The mixture Was Washed With saturated 
aqueous NaHCO3, Water and brine successively and dried. 
Evaporation of the solvent folloWed by titration With ether 
afforded 155 mg (68%) of cis-1-methyl-8-octyl-2,3,3a,4,5, 
9b-hexahydro-1H-pyrrolo[3,2-h]isoquinolin-8-ium iodide 
(ACO) as a broWn oil. 1H NMR (300 MHZ, CDCl3) 69.16 
(1H, s, C9-H), 9.03 (1H, d, J6.0 HZ, C7-H), 7.82 (1H, d, J6.0 
HZ, C6-H), 4.86 (2H, m. pyCHZ), 3.66 (1H, d, J8.4 HZ, 
C9b-H), 2.43 (3H, s, NCH3), 1.55—3.20 (9H, m, CH2+CH), 
1.99 (2H, m, pyCHZCHZ), 1.00—1.50 (10H, m, 5><CH2), 0.81 
(3H, t, J6.9 HZ, CH2CH3); 13C NMR (75 MHZ, CDCl3) 
6161.8, 143.5, 142.5, 138.2, 127.6, 63.4, 61.4, 55.8, 41.2, 
35.8, 32.1, 31.8, 30.0, 29.2><2, 27.8, 27.6, 26.2, 22.7, 14.2. 
EXAMPLE 2 
Preparation of cis-1-Methyl-8-nonyl-2,3,3a,4,5,9b 
hexahydro-1H-pyrrolo[3,2-h]-isoquinolin-8-ium 
iodide (ACN) 
To a stirred solution of cis-1-methyl-2,3,3a,4,5,9b 
hexahydro-1H-pyrrolo[3,2-h]isoquinoline (120 mg, 0.64 
mmol) in AcOH (2 ml) Was added 1-iodononane (488 mg, 
1.92 mmol). The mixture Was heated at re?ux under nitrogen 
for 3 days. AcOH Was evaporated and the residue Was 
dissolved in CHCl3. The mixture Was Washed With saturated 
aqueous NaHCO3, Water and brine successively and dried. 
Evaporation of the solvent folloWed by titration With ether 
afforded 222 mg (79%) of cis-1-methyl-8-nonyl-2,3,3a,4,5, 
9b-hexahydro-1H-pyrrolo[3,2-h]isoquinolin-8-ium iodide 
(ACN) as a broWn oil. 1H NMR (300 MHZ, CDCl3) 69.05 
(1H, s, C9-H), 9.03 (1H, d, J6.0 HZ, C7-H), 7.81 (1H, d, J6.0 
HZ, C6-H), 4.88 (2H, m. pyCHZ), 3.47 (1H, d, J8.7 HZ, 
C9b-H), 2.36 (3H, s, NCH3), 1.60—3.10 (9H, m, CH2+CH), 
2.00 (2H, m, pyCHZCHZ), 1.10—1.50 (12H, m, 6><CH2), 0.83 
(3H, t, J6.9 HZ, CH2CH3); 13C NMR (75 MHZ, CDCl3) 
6161.7, 143.4, 142.5, 139.2, 127.5, 63.5, 61.5, 55.9, 41.3, 
35.9, 32.1, 32.0, 30.3, 29.5, 29.3, 29.2, 28.2, 27.6, 26.2, 22.8, 
14.2. 
EXAMPLE 3 
Preparation of cis-8-Decyl-1-methyl-2,3,3a,4,5,9b 
hexahydro-1H-pyrrolo[3,2-h]-isoquinolin-8-ium 
iodide (ACD) 
To a stirred solution of cis-1-methyl-2,3,3a,4,5,9b 
hexahydro-1H-pyrrolo[3,2-h]isoquinoline (80 mg, 0.43 
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mmol) in AcOH (2 ml) Was added 1-iododecane (342 mg, 
1.28 mmol). The mixture Was heated at re?ux under nitrogen 
for 3 days. AcOH Was evaporated and the residue Was 
dissolved in CHCl3. The mixture Was Washed With saturated 
aqueous NaHCO3, Water and brine successively and dried. 
Evaporation of the solvent folloWed by titration With ether 
afforded 130 mg (67%) of cis-8-decyl-1-methyl-2,3,3a,4,5, 
9b-hexahydro-1H-pyrrolo[3,2-h]isoquinolin-8-ium iodide 
(ACD) as a broWn oil. 1H NMR (300 MHZ, CDCl3) 69.16 
(1H, s, C9-H), 9.14 (1H, d, J5.4 HZ, C7-H), 7.82 (1H, d, J6.0 
HZ, C6-H), 4.85 (2H, m. pyCHZ), 3.43 (1H, d, J8.4 HZ, 
C9b-H), 2.30 (3H, s, NCH3), 1.50—3.10 (9H, m, CH2+CH), 
1.96 (2H, m, pyCHZCHZ), 1.00—1.40 (14H, m, 7><CH2), 0.78 
(3H, t, J6.9 HZ, CHZCHB); 13C NMR (75 MHZ, CDCl3) 
6161.5, 143.4, 142.7, 138.9, 127.5, 63.3, 61.2, 55.8, 41.0, 
35.7, 32.1, 31.9, 30.1, 29.5, 29.4, 29.3, 29.2, 28.2, 27.3, 26.1, 
22.7, 14.2. 
EXAMPLE 4 
Preparation of cis-1-Methyl-8-undecyl-2,3,3a,4,5, 
9b-hexahydro-1H-pyrrolo[3,2-h]-isoquinolin-8-ium 
iodide (ACU) 
To a stirred solution of cis-1-methyl-2,3,3a,4,5,9b 
hexahydro-1H-pyrrolo[3,2-h]isoquinoline (120 mg, 0.64 
mmol) in AcOH (2 ml) Was added 1-iodoundecane (542 mg, 
1.92 mmol). The mixture Was heated at re?ux under nitrogen 
for 3 days. AcOH Was evaporated and the residue Was 
dissolved in CHCl3. The mixture Was Washed With saturated 
aqueous NaHCO3, Water and brine successively and dried. 
Evaporation of the solvent folloWed by titration With ether 
afforded 210 mg (70%) of cis-1-methyl-8-undecyl-2,3,3a,4, 
5,9b-hexahydro-1H-pyrrolo[3,2-h]isoquinolin-8-ium iodide 
(ACU) as a broWn oil. 1H NMR (300 MHZ, CDCl3) 69.16 
(1H, s, C9-H), 9.07 (1H, d, J6.0 HZ, C7-H), 7.81 (1H, d, J6.0 
HZ, C6-H), 4.82 (2H, m. pyCHZ), 3.44 (1H, d, J8.4 HZ, 
C9b-H), 2.29 (3H, s, NCH3), 1.50—3.10 (9H, m, CH2+CH), 
1.95 (2H, m, pyCHZCHZ), 1.00—1.40 (16H, m, 8><CH2), 0.76 
(3H, t, J6.9 HZ, CH2CH3); 13C NMR (75 MHZ, CDCl3) 
6161.5, 143.2, 142.4, 138.8, 127.5, 63.1, 61.0, 55.7, 41.0, 
35.6, 32.0, 31.8, 30.0, 29.51, 29.48, 29.4, 29.2, 29.1, 28.1, 
27.3, 26.0, 22.6, 14.1. 
EXAMPLE 5 
Preparation of cis-8-Dodecyl-1-methyl-2,3,3a,4,5, 
9b-hexahydro-1H-pyrrolo[3,2-h]-isoquinolin-8-ium 
iodide (ACDD) 
To a stirred solution of cis-1-methyl-2,3,3a,4,5,9b 
hexahydro-1H-pyrrolo[3,2-h]isoquinoline (120 mg, 0.64 
mmol) in AcOH (2 ml) Was added 1-iodoundecane (569 mg, 
1.92 mmol). The mixture Was heated at re?ux under nitrogen 
for 3 days. AcOH Was evaporated and the residue Was 
dissolved in CHCl3. The mixture Was Washed With saturated 
aqueous NaHCO3, Water and brine successively and dried. 
Evaporation of the solvent folloWed by titration With ether 
afforded 205 mg (66%) of cis-8-dodecyl-1-methyl-2,3,3a,4, 
5,9b-hexahydro-1H-pyrrolo[3,2-h]isoquinolin-8-ium iodide 
(ACDD) as a broWn oil. 1H NMR (300 MHZ, CDCl3) 69.08 
(1H, s, C9-H), 9.02 (1H, d, J6.3 HZ, C7-H), 7.79 (1H, d, J6.3 
HZ, C6-H), 4.90 (2H, m. pyCHZ), 3.48 (1H, d, J8.4 HZ, 
C9b-H), 2.36 (3H, s, NCH3), 1.50—3.10 (9H, m, CH2+CH), 
2.00 (2H, m, pyCHZCHZ), 1.10—1.40 (18H, m, 9><CH2), 0.85 
(3H, t, J6.9 HZ, CH2CH3); 13C NMR (75 MHZ, CDCl3) 
6161.5, 143.3, 142.5, 138.8, 127.5, 63.1, 61.0, 55.7, 41.0, 
35.6, 32.0, 31.9, 30.0, 29.6><2, 29.5, 29.4, 29.3, 29.1, 28.1, 
27.3, 26.0, 22.7, 14.1. 
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EXAMPLE 6 
Preparation of cis-1-Methyl-6-octyl-2,3,3a,4,5,9b 
hexahydro-1H-pyrrolo[2,3-f]-isoquinolin-6-iurn 
iodide (BCO) 
To a stirred solution of cis-1-rnethyl-2,3,3a,4,5,9b 
hexahydro-1H-pyrrolo[2,3-f]isoquinoline (120 mg, 0.64 
rnrnol) in AcOH (2 ml) Was added 1-iodooctane (460 mg, 
1.92 rnrnol). The mixture Was heated at re?ux under nitrogen 
for 3 days. AcOH Was evaporated and the residue Was 
dissolved in CHCl3. The mixture Was Washed With saturated 
aqueous NaHCO3, Water and brine successively and dried. 
Evaporation of the solvent folloWed by titration With ether 
afforded 155 mg (57%) of cis-1-rnethyl-6-octyl-2,3,3a,4,5, 
9b-hexahydro-1H-pyrrolo[2,3-f]isoquinolin-6-iurn iodide 
(BCO) as a broWn oil. 1H NMR (300 MHZ, CDCl3) 69.38 
(1H, d, J6.0 HZ, C7-H), 8.20 (1H, d, J7.5 HZ, C9-H), 7.95 
(1H, t, J7.0 HZ, C8-H), 4.82 (2H, rn. pyCHZ), 3.36 (1H, d, 
J8.4 HZ, C9b-H), 2.25 (3H, s, NCH3), 1.62—3.20 (11H, rn, 
CH2+CH), 100—1.50 (10H, rn, 5><CH2), 0.82 (3H, t, J6.9 HZ, 
CH2CH3); 13C NMR (75 MHZ, CDCl3) 6157.0, 145.8, 
144.8, 139.0, 125.3, 66.3, 59.0, 55.6, 40.6, 35.4, 31.8, 31.0, 
29.7, 29.2, 29.1, 28.3, 26.4, 24.6, 22.7, 14.2. 
EXAMPLE 7 
Preparation of cis-1-Methyl-6-nonyl-2,3,3a,4,5,9b 
hexahydro-1H-pyrrolo[2,3-f]-isoquinolin-6-iurn 
iodide (BCN) 
To a stirred solution of cis-1-rnethyl-2,3,3a,4,5,9b 
hexahydro-1H-pyrrolo[2,3-f]isoquinoline (100 mg, 0.53 
rnrnol) in AcOH (2 ml) Was added 1-iodononane (407 mg, 
1.59 rnrnol). The mixture Was heated at re?ux under nitrogen 
for 3 days. AcOH Was evaporated and the residue Was 
dissolved in CHCl3. The mixture Was Washed With saturated 
aqueous NaHCO3, Water and brine successively and dried. 
Evaporation of the solvent folloWed by titration With ether 
afforded 110 mg (47%) of cis-1-rnethyl-6-nonyl-2,3,3a,4,5, 
9b-hexahydro-1H-pyrrolo[2,3-f]isoquinolin-6-iurn iodide 
(BCN) as a broWn oil. 1H NMR (300 MHZ, CDCl3) 69.38 
(1H, d, J6.0 HZ, C7-H), 8.17 (1H, d, J7.5 HZ, C9-H), 7.93 
(1H, t, J7.0 HZ, C8-H), 4.82 (2H, rn. pyCHZ), 3.31 (1H, d, 
J8.4 HZ, C9b-H), 2.24 (3H, s, NCHB), 1.62—3.20 (11H, rn, 
CH2+CH), 1.10—1.50 (12H, rn, 6><CH2), 0.80 (3H, t, J6.6 HZ, 
CH2CH3); 13C NMR (75 MHZ, CDCl3) 6156.9, 145.7, 
144.6, 139.0, 125.2, 66.2, 58.9, 55.6, 40.6, 35.3, 31.8, 30.9, 
29.7, 29.3, 29.2><2, 28.3, 26.3, 24.5, 22.7, 14.1. 
EXAMPLE 8 
Preparation of cis-6-Decyl-1-rnethyl-2,3,3a,4,5,9b 
hexahydro-1H-pyrrolo[2,3-f]-isoquinolin-6-iurn 
iodide (BCD) 
To a stirred solution of cis-1-rnethyl-2,3,3a,4,5,9b 
hexahydro-1H-pyrrolo[2,3-f]isoquinoline (100 mg, 0.53 
rnrnol) in AcOH (2 ml) Was added 1-iododecane (428 mg, 
1.5 9 rnrnol). The mixture Was heated at re?ux under nitrogen 
for 3 days. AcOH Was evaporated and the residue Was 
dissolved in CHCl3. The mixture Was Washed With saturated 
aqueous NaHCO3, Water and brine successively and dried. 
Evaporation of the solvent folloWed by titration With ether 
afforded 106 mg (44%) of cis-6-decyl-1-rnethyl-2,3,3a,4,5, 
9b-hexahydro-1H-pyrrolo[2,3f]isoquinolin-6-iurn iodide 
(BCD) as a broWn oil. 1H NMR (300 MHZ, CDCl3) 69.34 
(1H, d, J6.3 HZ, C7-H), 8.20 (1H, d, J7.5 HZ, C9-H), 7.93 
(1H, t, J6.9 HZ, C8-H), 4.80 (2H, rn. pyCHZ), 3.38 (1H, d, 
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J81 HZ, C9b-H), 2.23 (3H, s, NCH3), 1.64—3.30 (11H, rn, 
CH2+CH), 1.10_1.50 (14H, rn, 7><CH2), 0.80 (3H, 1, J6.6 HZ, 
CH2CH3); 13c NMR (75 MHZ, CDC13) 6156.9, 145.8, 
144.6, 138.8, 125.3, 66.2, 58.9, 55.5, 40.5, 35.3, 31.9, 30.9, 
29.6, 29.5, 29.4, 29.3, 29.2, 28.2, 26.3, 24.6, 22.7, 14.1. 
EXAMPLE 9 
Preparation of cis-1-Methyl-6-undecyl-2,3,3a,4,5, 
9b-hexahydro-1H-pyrrolo[2,3-f]-isoquinolin-6-iurn 
iodide (BCU) 
To a stirred solution of cis-1-rnethyl-2,3,3a,4,5,9b 
hexahydro-1H-pyrrolo[2,3-f]isoquinoline (80 mg, 0.43 
rnrnol) in AcOH (2 ml) Was added 1-iodoundecane (361 mg, 
1.29 rnrnol). The mixture Was heated at re?ux under nitrogen 
for 3 days. AcOH Was evaporated and the residue Was 
dissolved in CHCl3. The mixture Was Washed With saturated 
aqueous NaHCO3, Water and brine successively and dried. 
Evaporation of the solvent folloWed by titration With ether 
afforded 90 mg (45%) of cis-1-rnethyl-6-undecyl-2,3,3a,4, 
5,9b-hexahydro-1H-pyrrolo[2,3-f]isoquinolin-6-iurn iodide 
(BCU) as a broWn oil. 1H NMR (300 MHZ, CDCl3) 69.39 
(1H, d, J6.3 HZ, C7-H), 8.19 (1H, d, J7.8 HZ, C9-H), 7.94 
(1H, t, J6.9 HZ, C8-H), 4.82 (2H, rn. pyCHZ), 3.34 (1H, d, 
J8.4 HZ, C9b-H), 2.23 (3H, s, NCHB), 1.65—3.30 (11H, rn, 
CH2+CH), 1.10—1.50 (16H, rn, 8><CH2), 0.82 (3H, t, J6.6 HZ, 
CHZCHB); 13C NMR (75 MHZ, CDCl3) 6156.9, 145.9, 
144.7, 139.0, 125.3, 66.3, 59.0, 55.6, 40.6, 35.4, 32.0, 31.0, 
29.69, 29.65, 29.61, 29.5, 29.4, 29.2, 28.3, 26.4, 24.6, 22.8, 
14.2. 
EXAMPLE 10 
Preparation of cis-6-Dodecyl-1-rnethyl-2,3,3a,4,5, 
9b-hexahydro-1H-pyrrolo[2,3-f]-isoquinolin-6-iurn 
iodide (BCDD) 
To a stirred solution of cis-1-rnethyl-2,3,3a,4,5,9b 
hexahydro-1H-pyrrolo[2,3-f]isoquinoline (100 mg, 0.53 
rnrnol) in AcOH (2 ml) Was added 1-iodoundecane (474 mg, 
1.5 9 rnrnol). The mixture Was heated at re?ux under nitrogen 
for 3 days. AcOH Was evaporated and the residue Was 
dissolved in CHCl3. The mixture Was Washed With saturated 
aqueous NaHCO3, Water and brine successively and dried. 
Evaporation of the solvent folloWed by titration With ether 
afforded 116 mg (45%) of cis-6-dodecyl-1-rnethyl-2,3,3a,4, 
5,9b-hexahydro-1H-pyrrolo[2,3-f]isoquinolin-6-iurn iodide 
(BCDD) as a broWn oil. 1H NMR (300 MHZ, CDCl3) 69.40 
(1H, d, J6.0 HZ, C7-H), 8.17 (1H, d, J7.8 HZ, C9-H), 7.94 
(1H, t, J6.9 HZ, C8-H), 4.84 (2H, rn. pyCHZ), 3.31 (1H, d, 
J8.4 HZ, C9b-H), 2.22 (3H, s, NCHB), 1.64—3.30 (11 H, In, 
CH2+CH), 1.10—1.50 (18H, rn, 5><CH2), 0.82 (3H, t, J6.6 HZ, 
CHZCHB); 13C NMR (75 MHZ, CDCl3) 6156.6, 145.7, 
144.8, 139.0, 125.3, 66.3, 59.0, 55.6, 40.6, 35.4, 32.0, 31.0, 
29.7><3, 29.6, 29.5, 29.4, 29.3, 28.4, 26.4, 24.6, 22.8, 14.2. 
EXAMPLE 11 
[3H]-DA Release Assay 
Rat striatal slices (500 urn thickness, 6—8 mg Wet Weight) 
Were incubated for 30 minutes in Kreb’s buffer (118 nM 
NaCl, 4.7 nM KCl, 1.2 nM MgCl2, 1.0 nM NaH2PO4, 1.3 
nM CaCl2, 11.1 nM glucose, 25 nM NaHCO3, 0.1.1 nM 
L-ascorbic acid, and 0.004 nM disodiurn EDTA; pH 7.4, and 
saturated With 95% O2/5% CO2) in a metabolic shaker at 34° 
C. Slices Were rinsed With 15 ml of fresh buffer and 
incubated for an additional 30 minutes in fresh buffer 
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containing 0.1 pM [3H]-DA (6 slices/3 ml). Subsequently, 
slices Were rinsed With 15 ml of fresh buffer and transferred 
to a glass superfusion chamber. Slices Were superfused (1.0 
ml/min) for 60 minutes With Kreb’s buffer containing 
nomifensine (10 pM and pargyline (10 pM) and maintained 
at 34° C., pH 7.4, With continual aeration (95% O2/5% CO2). 
TWo 5 minute samples (5 ml each) Were collected to 
determine basal out?oW of [3H]-DA. N-Substituted confor 
mationally restricted nicotine analogs Were added to the 
superfusion buffer after the collection of the second sample 
and remained in the buffer until 12 consecutive 5 minute 
samples Were collected. Subsequently, S-(—)-nicotine (10 
pM) Was added to the buffer and an additional 12 consecu 
tive ?ve minute samples Were collected. At the end of the 
experiment, each slice Was solubiliZed and the [3H] content 
of the tissue determined. 
Radioactivity in the superfusate and tissue samples Was 
determined by liquid scintillation spectroscopy. Fractional 
release for each tritium collected in each sample by the total 
tritium present in the tissue at the time of sample collection 
and Was expressed as a percentage of total tritium. Basal 
[3H]out?oW Was calculated from the average of the tritium 
collected in the tWo ?ve minute samples just before addition 
of the conformationally restricted nicotine analog. The sum 
of the increase in collected tritium resulting from either 
exposure to the test compound or exposure to nicotine in the 
absence and presence of the test compound equaled total 
[3H]over?oW. [3H]Over?oW Was calculated by subtracting 
the [3H]out?oW during an equivalent period of prestimula 
tion from the values in samples collected during and after 
drug exposure. Inasmuch as the radiolabelled compounds 
Were not separated and identi?ed, the tritium collected in 
superfusate is referred to as either [3H]out?oW or [3H] 
over?oW, rather than as [3H]-DA. [3H]Over?oW primarily 
represents [3H]-DA in the presence of nomifensine and 
pargyline in the superfusion buffer. 
The conformationally restricted nicotine analogs Were 
evaluated for their ability to evoke [3H] release from rat 
striatal slices at tWo concentrations (0.1 and 1 pM). In 
addition, the classical competitive nicotinic antagonist 
DHBE Was also examined in this assay for comparison. 
None of the compounds examined had any signi?cant [3H] 
DA releasing properties in this assay at concentrations beloW 
10 pM, but all the compounds exhibited intrinsic activity at 
10 pM Since striatal NIC-evoked [3H]-DA: release is 
thought to be mediated through a mechanism involving the 
(x3[32-containing receptor subtype, these compounds do not 
possess signi?cant agonist activity beloW 10 pM at this 
putative receptor subtype. 
The conformationally restricted bridged NONI analogs 
Were also evaluated for their ability to inhibit NIC evoked 
[3H]-DA release. In these experiments, the striatal slices 
Were superfused for 60 minutes With various concentrations 
of the analogs prior to NIC (10 pM) exposure. Antagonist 
activity Was evaluated by comparing the NIC-evoked [3H] 
over?oW in the absence and presence of the analogs. The 
potency of these bridged NONI analogs for inhibition of 
NIC-evoked [3H]-DA release from rat striatal slices is 
illustrated in Table 1 by a comparison of their IC5O values. 
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TABLE 1 
Comparative ICSUS for Syn and Anti Rotamer Analogs in the 
S—(—)—NIC-evoked [3HlDA Release Assaya 
3No signi?cant intrinsic agonist activity Was observed for any of these 
compounds in this assay beloW 10 ,uM. 
EXAMPLE 12 
[3H]-NIC Binding Assay 
Striata from tWo rats Were dissected, pooled, and homog 
eniZed With a Tekmar polytron in 10 vol of ice-cold modi?ed 
Krebs-HEPES buffer (20 mM HEPES, 118 mM NaCl, 4.8 
mM KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, adjusted to pH 
7.5). The homogenates Were incubated at 37° C. for 5 
minutes and centrifuged at 15,000 g for 20 minutes. The 
pellet Was resuspended in 10 volumes of ice-cold MilliQ 
Water, incubated for 5 minutes at 37° C., and centrifuged at 
15,000 g for 20 minutes. The second pellet Was then 
resuspended in 10 volumes of fresh ice-cold 10% Krebs 
HEPES buffer, incubated at 37° C., and centrifuged at 
15,000 g for 20 minutes. The latter sequence of 
resuspension, incubation, and centrifugation Was repeated. 
The pellet Was froZen under fresh 10% Krebs-HEPES buffer 
and stored at —40° C. until assayed. Upon assay, the pellet 
Was resuspended in the Krebs-HEPES buffer, incubated at 
37° C. for 5 minutes, and centrifuged at 15,000 g for 20 
minutes. The ?nal pellet Was resuspended in 3.6 ml ice-cold 
MilliQ Water Which provided for approximately 200 pg 
protein per 100 pl aliquot. Competition assays Were per 
formed in triplicate in a ?nal volume of 200 pl Krebs 
HEPES buffer containing 250 mmol Tris buffer (pH 7.5 at 4° 
C.). Reactions Were initiated by addition of 100 pl of 
membrane suspension to 3 mM [3H]-NIC (50 pl). and one of 
at least nine concentrations of analog (50 pl). After a 90 
minutes incubation at 40° C., reactions Were terminated by 
US 6,503,922 B2 
13 
dilution of the samples With 3 ml of ice-cold Krebs-HEPES 
buffer followed immediately by ?ltration through Whatman 
GF/B. glass ?ber ?lters (presoaked in 0.5% 
polyethyleneimine) using a Brandel Cell Harvester. Filters 
Were rinsed three times With. 3 ml of ice-cold Krebs-HEPES 
buffer, transferred to scintillation vials, and 5 ml scintillation 
cocktail (Research Products International Corp., Mt. 
Prospect, Ill.) added. Nonspeci?c binding determined in 
triplicate Was de?ned as binding in the presence of 10 pM 
NIC. Binding parameters Were determined using the 
Weighted, least squares regression. 
The conformationally restricted nicotine analogs Were 
evaluated for their ability to displace [3H]-NIC binding from 
rat striatal membranes. The results are summariZed in Table 
2. Furthermore, the displacement by the analogs Was com 
pared to those produced by NONI, NDNI, and DHBE. All of 
the compounds examined displaced [3H]-NIC binding With 
much loWer af?nities than DHBE. The 8-carbon alkyl chain 
bridged nicotinium compounds (ACO and BCO) had much 
loWer affinity for the [3H]-NIC binding site compared to 
NONI; surprisingly, the 10-carbon alkyl chain bridged nico 
tiniumr compounds (ACD and BCD) lost their ability to 
interact With this binding site compared to the high affinity 
of NDNI. Thus, the unique conformationally restricted ste 
reochemistry presented by these analogs to the (x462 
containing receptor subtype is not recogniZed by this sub 
type. 
TABLE 2 
Speci?c Binding of [3H]—NIC to Rat Striatal Nicotinic Acetylcholine 
Receptors in the Presence of Conformationally Constrained NONI Analogs 
Concentration (MM)a 
Compound 0 1 10 100 
NONI 42.0 r 3.0 42.6 r 2.6 37.5 r 2.3 14.0 r 1.3 
NDNI 42.0 r 3.3 9.2 r 1.0 0.5 r 0.2 NDb 
DHBE 55.0 r 3.0 18.0 r 5.0 4.0 r 1.0 ND 
ACO 43.4 r 1.0 44.5 r 0.4 42.2 r 0.5 30.2 r 6.9 
ACN 51.2 r 2.9 49.8 r 3.6 48.9 r 2.9 30.2 r 2.2 
ACD 50.9 r 2.7 50.3 r 3.7 52.1 r 2.6 37.0 r 1.7 
ACU 47.1 r 2.1 51.3 r 2.0 49.0 r 0.3 42.7 r 2.1 
ACDD 44.7 r 1.7 49.5 r 0.7 49.8 r 2.9 44.5 r 1.7 
BCO 51.2 r 1.5 50.5 r 1.2 39.7 r 1.4 13.5 r 0.5 
BCN 48.0 r 2.9 49.6 r 1.2 47.7 r 2.1 36.2 r 0.3 
BCD 53.7 r 0.5 54.9 r 0.7 54.4 r 1.1 47.9 r 2.8 
BCU 53.7 r 0.5 56.1 r 0.6 53.9 r 1.2 37.3 r 1.8 
BCDD 45.8 r 3.9 43.7 r 4.5 43.0 r 4.7 34.0 r 2.1 
3Data are expressed as fmol/mg of protein, mean : S.E.M of 3 indepen 
dent experiments. Speci?c binding is calculated as the difference between 
the total binding of 3 nM [3H]—NIC to the receptors alone and its nonspe 
ci?c binding in the presence of 10 ,uM cold nicotine. 
bND: Not determined. 
EXAMPLE 13 
[3H]-MLA Binding Assay 
Na'ive male Sprague-DaWley rats Weighing 220—250 g 
Were housed tWo per cage With free access to food and Water. 
All procedures in these studies Were approved by the Insti 
tutional Animal Care and Use Committee at the University 
of Kentucky. The animals Were killed by decapitation, each 
brain Was quickly removed and placed on ice-cold glass 
platform. The brain Was dissected into the Whole brain tissue 
Without cortex, striatum and cerebellum and Was froZen in 
liquid nitrogen and stored at —70° C. until use. 
The brain tissue Was homogeniZed With a Tekmar Poly 
tron (setting 40) in 20 volumes of ice-cold hypotonic buffer 
(2 mM HEPES, 14.4 mM NaCl, 0.15 mM KCl, 0.2 mM 
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CaCl2 and 0.1 mM MgSO4, pH=7.5). The homogenate Was 
incubated at 37° C. for 10 minutes and centrifuged at 
25,000><g for 15 minutes at 40° C. The pellet Was Washed 3 
times more by resuspension in the 20 volumes of the same 
buffer and centrifugation at the above parameters. The ?nal 
pellet Was stored at —20° C. under 4.6 ml of the incubation 
buffer and Was suspended just before the incubation With 
radioligand. 
The binding of [3H]methyllycaconitine ([3H]MLA) to 
probe ot7-type neuronal nicotinic acetylcholine receptors 
Was measured using a modi?cation of the method of Davies 
et al., “Characterisation of the binding of [3H] 
methyllycaconitine: a neW radioligand for labelling ot7-type 
neuronal nicotinic acetylcholine receptors,’ 
Neuropharmacology, 38, 679—690 (1999). [3H]-MLA (25.4 
Ci/mmol) Was purchased from Tocris Cookson Ltd., Bristol, 
UK. Binding Was performed in duplicate, in a ?nal volume 
of 250 pl of the incubation medium, containing 20 mM 
HEPES, 144 mM NaCI, 1.5 mM KCl, 2 mM CaCI2, 1 mM 
MgSO4 and 0.05% BSA, pH=7.5. Reaction Was initiated by 
the addition of 100 pl of membrane suspension to the 
samples containing a desired concentration t of test com 
pounds and 2.5 mM [3H]-MLA (?nal concentration) and 
incubated for 2 hours at room temperature. Total binding 
Was measured in the absence of unlabelled ligand and 
nonspeci?c binding Was determined in the presence of 1 pM 
unlabelled MLA. The binding reaction Was terminated by 
dilution of samples With 3 ml of ice-cold incubation buffer 
folloWed by immediate ?ltration through presoaked in 0.5% 
polyetylenimine glass ?ber ?lters (S&S, grade #32) using a 
Brandel harvester system. Filters Were rinsed three times 
With 3 ml of ice-cold buffer, transferred to scintillation vials 
and 4 ml of scintillation cocktail Was added. Protein Was 
measured using the Bradford dye-binding procedure With 
bovine serum albumin as the standard. 
In order to determine if these compounds have selectivity 
at the (x362 receptor subtype, the bridged NONI analogs 
Were evaluated for their ability to displace [3H]-MLA bind 
ing from rat brain membranes, as a re?ection of their 
interaction With the (x7 receptor (Table 3). In addition, the 
classical (x7 receptor antagonist ot-bungarotoxin Was also 
examined in this assay for comparison. ot-Bungarotoxin 
afforded a Ki value of 28.615 .4 nM in the above assay. The 
results from the competition binding assay shoWed that none 
of the conformationally constrained compounds possessed 
any signi?cant binding af?nity in the [3H]-MLA assay. The 
percentage control of 2.5 nM [3H]-MLA binding to the rat 
brain membrane preparation in the presence of 10 pM of 
bridged NONI analogs ranged from 92.3 to 101.9, indicating 
that at a 10 pM concentration, the above compounds had no 
signi?cant af?nity for the (X7 receptor subtype. 
TABLE 3 
[3H]—MLA Binding in the Presence of Conformationally 
Restrained NONI and NDNI Analogs 
% Control [3H]-MLA 
Compound Binding at 10 ,uM" 
ACO 91.5 
ACN 100.7 
ACD 101.9 
ACU 100.4 
ACDD 101.9 
BCO 93.6 
BCN 94.0 
BCD 96.2 
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TABLE 3-continued 
[3H]—MLA Binding in the Presence of Conformationally 
Restrained NONI and NDNI Analogs 
% Control [3H]-MLA 
Compound Binding at 10 ,uM" 
BCU 92.3 
BCDD 94.2 
*Data are expressed as % Whole brain binding relative to control (2.5 nM 
[3H]-MLA). 
The purpose of the above description and examples is to 
illustrate some embodiments of the present invention With 
out implying any limitation. It Will be apparent to those of 
skill in the art that various modi?cations and variations may 
be made to the composition and method of the present 
invention Without departing from the spirit or scope of the 
invention. All patents and publications cited herein are 
incorporated by reference in their entireties. 
We claim: 
1. A compound of the following III or IV; 
III 
Wherein 
A and B each independently represent CH2 or CHZCHZ; 
R1 represents hydrogen, loWer alkyl or an aromatic group 
containing species; 
R2 represents hydrogen or loWer alkyl; 
R3, R4 and R5 each independently represent hydrogen; 
alkyl; substituted alkyl; cycloalkyl; substituted 
cycloalkyl; alkenyl; substituted alkenyl; alkynyl; sub 
stituted alkynyl; aryl; substituted aryl; alkylaryl; sub 
stituted alkylaryl; arylalkyl; substituted arylalkyl; ary 
lalkenyl; substituted arylalkenyl; arylalkynyl; 
substituted arylalkynyl; heterocyclic; substituted het 
erocyclic; tri?uoromethyl; halogen; cyano; nitro; S(O) 
Y2, S(O)2Y2, S(O)2OY2 or S(O)2NHY2, Wherein each 
Y2 is hydrogen, loWer alkyl, alkenyl, alkynyl or aryl, 
provided that When R3, R4 or R5 is S(O)Y2, Y2 is not 
hydrogen, and further provided that When Y2 is alkenyl 
or alkynyl, the site of unsaturation is not conjugated 
With a heteroatom; C(O)Y3, Wherein Y3 is hydrogen, 
alkyl, substituted alkyl, alkoXy, alkylamino, alkenyl, 
15 
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substituted alkenyl, alkynyl, substituted alkynyl, aryl, 
substituted aryl, aryloXy, arylamino, alkylaryl, substi 
tuted alkylaryl, arylalkyl, substituted arylalkyl, 
arylalkenyl, substituted arylalkenyl, arylalkynyl, sub 
stituted arylalkynyl, heterocyclic, substituted heterocy 
clic or tri?uoromethyl, provided, however, that the 
carbonyl functionality is not conjugated With an alkenyl 
or alkynyl functionality; OY4 or N(Y“)2 Wherein Y4 is 
hydrogen, alkyl, substituted alkyl, cycloalkyl, substi 
tuted cycloalkyl, alkenyl, subtituted alkenyl, alkynyl, 
substituted alkynyl, aryl, substituted aryl, alkylaryl, 
substituted alkylaryl, arylalkyl, substituted arylalkyl, 
arylalkenyl, substituted arylalkenyl, arylalkynyl, sub 
stituted arylalkynyl, heterocyclic, substituted 
heterocyclic, acyl, tri?uoromethyl, alkylsulfonyl or 
arylsulfonyl, provided that the OY4 or N(Y“)2 func 
tionality is not conjugated With an alkenyl or alkynyl 
functionality; SY5 Wherein Y5 is hydrogen, alkyl, sub 
stituted alkyl, cycloalkyl, substituted cycloalkyl, 
alkenyl, subtituted alkenyl, alkynyl, substituted 
alkynyl, aryl, substituted aryl, alkylaryl, substituted 
alkylaryl, arylalkyl, substituted arylalkyl, arylalkenyl, 
substituted arylalkenyl, arylalkynyl, substituted 
arylalkynyl, heterocyclic, substituted heterocyclic or 
tri?uoromethyl, provided that the SY5 functionality is 
not conjugated With an alkenyl or alkynyl functionality; 
R6 represents alkyl, substituted alkyl, cycloalkyl, substi 
tuted cycloalkyl, alkenyl, subtituted alkenyl, alkynyl, 
substituted alkynyl, aryl, substituted aryl, arylalkyl, 
substituted arylalkyl, arylalkenyl, substituted 
arylalkenyl, arylalkynyl, substituted arylalkynyl, het 
erocyclic or substituted heterocyclic; and 
X represents chlorine, bromine, iodine, HSO4, 1/2SO2, 
2. The compound according to claim 1, 
C1—C1Oalkyl. 
3. The compound according to 
C1—C6alkyl. 
4. The compound according to 
methyl. 
5. The compound according to 
ethyl. 
6. The compound according to 
isopropyl. 
7. The compound according to 
isobutyl. 
8. The compound according to claim 1, Wherein R2 is 
hydrogen. 
9. The compound according to claim 1, Wherein R3, R4 
and R5 are individually selected from hydrogen, halogen, 
alkyl, or alkanoyl. 
10. The compound according to claim 1, Wherein R6 is a 
C4—C19 unbranched alkyl. 
11. The compound according to claim 1, Wherein X is 
iodine. 
12. The compound according to claim 1, Wherein said 
compound is cis-1-methyl-8-octyl-2,3,3a,4,5,9b-hexahydro 
1H-pyrrolo[3,2-h]isoquinolin-8-ium iodide (ACO). 
13. The compound according to claim 1, Wherein said 
compound is cis-1-methyl-8-nonyl-2,3,3a,4,5,9b 
heXahydro-1H-pyrrolo[3,2-h]isoquinolin-8-ium iodide 
(ACN). 
14. The compound according to claim 1, Wherein said 
compound is cis-8-decyl-1-methyl-2,3,3a,4,5,9b 
heXahydro-1H-pyrrolo[3,2-h]isoquinolin-8-ium iodide 
(ACD). 
15. The compound according to claim 1, Wherein said 
compound is cis-1-methyl-8-undecyl-2,3,3a,4,5,9b 
heXahydro-1H-pyrrolo[3,2-h]isoquinolin-8-ium iodide 
(ACU). 
Wherein R1 is 
claim 1, Wherein R1 
claim 1, Wherein R1 
claim 1, Wherein R1 
claim 1, Wherein R1 
claim 1, Wherein R1 
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16. The compound according to claim 1, wherein said 
compound is cis-8-dodecyl-1-methyl-2,3,3a,4,5,9b 
heXahydro-1H-pyrrolo[3,2-h]isoquinolin-8-ium iodide 
(ACDD). 
17. The compound according to claim 1, Wherein said 
compound is cis-1-methyl-6-octyl-2,3,3a,4,5,9b-heXahydro 
1H-pyrrolo[2,3-f]isoquinolin-8-ium iodide (BCO). 
18. The compound according to claim 1, Wherein said 
compound is cis-1-methyl-6-nonyl-2,3,3a,4,5,9b 
heXahydro-1H-pyrrolo[2,3-f]isoquinolin-6-ium iodide 
(BCN). 
19. The compound according to claim 1, Wherein said 
compound is cis-6-decyl-1-methyl-2,3,3a,4,5,9b 
heXahydro-1H-pyrrolo[2,3-f]isoquinolin-6-ium iodide 
(BCD). 
20. The compound according to claim 1, Wherein said 
compound is cis-1-methyl-6-undecyl-2,3,3a,4,5,9b 
heXahydro-1H-pyrrolo[2,3-f]isoquinolin-6-ium iodide 
(BCU). 
21. The compound according to claim 1, Wherein said 
compound is cis-6-dodecyl-1-methyl-2,3,3a,4,5,9b 
heXahydro-1H-pyrrolo[2,3-f]isoquinolin-6-ium iodide 
(BCDD). 
22. A compound according to claim 1, Wherein the ring 
junction betWeen a and b rings is cis or trans. 
23. A compound according to claim 1, Wherein said 
compound is substantially optically pure. 
24. A compound according to claim 1, Wherein said 
compound is a racemic mixture or a diastereometric mixture. 
25. A method of binding a nicotine receptor With a 
compound according to claim 1, Wherein said compound is 
a nicotinic receptor antagonist. 
26. A method of binding a nicotine receptor With a 
compound according to claim 1, Wherein said compound 
inhibits NIC-evoked [3H]-DA release. 
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27. A method of binding a nicotine receptor With a 
compound according to claim 1, Wherein said compound 
inhibits [3]-NIC binding. 
28. A method of inhibiting the binding of a nicotinic 
receptor comprising the step of administering of a pharma 
ceutically effective amount of a compound according to 
claim 1. 
29. A method of treating abuse of nicotinic receptor 
agonists, addiction to tobacco products, or addiction to 
nicotine comprising the step of administering an effective 
amount of a compound according to claim 1. 
30. A method of treating AlZheimer’s disease comprising 
the step of administering of a pharmaceutically effective 
amount of a compound according to claim 1. 
31. A method of treating Parkinson’s disease comprising 
the step of administering of a pharmaceutically effective 
amount of a compound according to claim 1. 
32. A method of treating pain, comprising the step of 
administering of a pharmaceutically effective amount of a 
compound according to claim 1. 
33. A method of binding a nicotine receptor With a 
compound according to claim 1, Wherein said compound 
competitively inhibits central nervous system acting nico 
tinic receptor agonists. 
34. A method of binding a nicotine receptor With a 
compound according to claim 1, Wherein said compound 
acts at the putative (x362 neuronal nicotinic receptor in the 
central nervous system. 
35. A method of treating irritable boWel syndrome, com 
prising the step of administering of a pharmaceutically 
effective amount of a compound according to claim 1. 
36. A method of treating calitis, comprising the step of 
administering of a pharmaceutically effective amount of a 
compound according to claim 1. 
* * * * * 
